SecBot SecBot
SECBOTREPLAY Home › Report › MRVI

MRVI · Maravai LifeSciences refinanced its prior credit agreement by entering…

MARAVAI LIFESCIENCES HOLDINGS, INC. · 8-K filed Jun 3, 2026 at 08:31 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 3, 2026 at 08:31 ET

Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 million revolving credit facility, maturing June 2, 2032. Proceeds from the new term loan, combined with ~$98.5 million cash on hand, were used to repay $242.9 million in prior debt, reducing total debt by ~$92.9 million and extending the maturity from October 2027 to June 2032. The transaction materially reduces leverage, extends runway, and maintains liquidity, though a variable-rate interest structure introduces rate exposure.

  • New $150.0M term loan facility and $30.0M revolver, both maturing June 2, 2032; new term loan reduces outstanding debt from ~$242.9M to $150.0M.
  • Proceeds from the new term loan plus ~$98.5M cash on hand used to fully prepay and terminate the prior Credit Agreement (due October 2027).
  • Interest rate: Term SOFR + 5.00% per annum; stepdown to 4.75% if first lien net leverage ratio ≤ 3.00x.
  • Financial covenant (springing): if revolver usage ≥ 40% of commitments, max first lien net leverage ratio of 6.50x.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access